XOMA (XOMA)

Executive Summary

XOMA Royalty Corporation operates a capital-light business model as a biotech royalty aggregator, acquiring economic rights to future milestone and royalty payments from pre-commercial therapeutic assets developed by pharmaceutical and biotech partners. With a diversified portfolio of over 120 assets across multiple therapeutic areas, XOMA provides non-dilutive funding to its partners while generating revenue streams from milestone payments and royalties as assets progress through development and commercialization. The company’s strategy reduces risk through diversification and allows it to benefit from the success of a broad range of innovative therapies. Financially, XOMA has demonstrated steady revenue growth driven by milestone payments from its partnered programs. The company maintains a strong balance sheet with ample liquidity to pursue new royalty acquisitions. Key drivers for future performance include the advancement of late-stage assets in its portfolio, particularly those in Phase 3 or under regulatory review, which could trigger significant milestone payments. Management remains focused on expanding the portfolio through disciplined acquisitions, aiming to enhance shareholder value as partnered assets approach potential market approvals.

Upcoming Catalysts (preview)

• Q3 2026Milestone payment from partnered Phase 3 asset (e.g., in oncology or immunology)60% success
• Q4 2026Announcement of new royalty acquisition deal50% success
• Q2 2026Quarterly earnings report with revenue beat due to higher-than-expected milestone income65% success